August 19, 2010
Nutra Pharma (OTCBB:NPHC) has begun the drug registration process in India for its Nyloxin line of pain relievers; the Company is also seeking a relationship with an India-based pharmaceutical company to support the launch, marketing and sales of Nyloxin throughout India.
Nutra Pharma Corporation, a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), Multiple Sclerosis (MS) and Pain, announced today that it has begun the drug registration process in India for its Nyloxin line of pain relievers.
According to a 1998 study published in the Journal of the American Medical Association (JAMA), it was estimated that 19% of patients evaluated in India suffered from persistent pain. An additional 2007 report from the Journal of Pain and Symptom Management, documented that only 0.4% of India’s population in need of opioids for pain relief had access to them.
“India represents one of the more significant international market opportunities for Nyloxin,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “With the population of India exceeding a billion people and with limited patient access to opioid-based pain relievers throughout the country, India presents a potentially significant customer base for Nyloxin,” he added.
Nyloxin, which was first introduced in November 2009 as a treatment for moderate to severe, Stage 2, chronic pain, is currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin is also offered in an extra strength formula for more advanced, Stage 3, chronic pain.
“We are working diligently to complete all of the steps required to finalize this drug registration and move forward with launching Nyloxin in India,” explained David Isserman, Chief Marketing Officer of Nutra Pharma Corporation. “Concurrently, we are seeking a relationship with a qualified India-based distributor that can offer both the financial resources and the local distribution and marketing knowledge required to successfully launch and support sales of Nyloxin throughout the country,” he concluded.
About Nutra Pharma Corp.
Nutra Pharma Corporation (OTCBB:NPHC) (the "Company") operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The Company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Additionally, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities. The Company's wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria (NTM). Nutra Pharma continues to identify intellectual property and companies in the biotechnology arena that it investigates about possibly acquiring or establish strategic partnerships with.
www.undiscoveredequities.net
www.nutrapharma.com
www.Cobroxin.com
Undiscovered Equities is currently offering a complimentary trial subscription.
To view our newsletter on a complimentary trial basis and take advantage of our other services go to www.undiscoveredequities.com and join our email list on our home page.
Sincerely,
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
101 Plaza Real, Suite 212
Boca Raton, FL 33432
www.undiscoveredequities.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment